The call for nominations for the new Executive Committee is now open! We are seeking motivated and committed scientists to join the Committee and contribute to advancing the adoption of in silico medicine through leadership, collaboration, and community engagement.
The European Medicines Agency (EMA) has introduced a dedicated pilot procedure for scientific advice and protocol assistance on model-informed drug development (MIDD) — a significant step forward for the in silico community and a clear regulatory signal that quantitative modelling evidence is coming of age.
Our scientific officer, Janaki Raman, joined the global regulatory affairs community in Lisbon for RAPS Euro Convergence 2026 — and in silico medicine was firmly on the agenda.
The VPH Society will award up to six Travel Vouchers to support VPH student members attending the VPH 2026 Conference in Milan, covering travel, accommodation, and living expenses. Applications will be evaluated based on scientific merit, diversity, and inclusion criteria.
The VPH Best Presentation Award recognises the best oral presentation delivered by a VPH student member at the VPH 2026 Conference. The winner will receive a certificate and a €500 cash prize.
VPH – The Society for In Silico Medicine is a partner in the DT4PH project. On 10 June 2026, the project hosts a one-day event in Leuven bringing together clinicians, researchers, industry, regulators, and patients to explore how digital twins and AI can be responsibly implemented in personalised healthcare.
To address this question DigiSoc and Ethics@KU Leuven will host an interdisciplinary lunch workshop on 7 May 2026 in Leuven.
The European Medicines Agency (EMA) has announced the successful adoption of ICH M15 (Step 5), establishing a harmonized international framework for planning, evaluating, and communicating Model informed Drug Development (MIDD) evidence.
The U.S. Food and Drug Administration (FDA) has released updated guidance aimed at strengthening how patient perspectives are incorporated into medical device decision-making throughout the total product life cycle.
Three important European consultations are currently open for feedback. These initiatives represent key opportunities to help shape policy and regulatory frameworks impacting research, innovation, and healthcare across Europe.
